Focus on injectable formulations in highly pharmacologically active areas

「In the pharmaceutical manufacturing and marketing business, we are proceeding with construction of the Zao No. 2 Plant to fulfill our responsibility to ensure a stable supply and respond to further growth in demand, and the plant was completed in June 2026. Regarding operations, we are preparing to bring forward the planned start from July 2027 to March 2027 to ensure a stable supply of core products for which demand from medical institutions is high.」

「Our group has met the standards required by Japanese GMP (Good Manufacturing Practice standards for the manufacture and quality control of pharmaceuticals) and has earned customers' trust by enhancing the quality-control capabilities regarded as most important in pharmaceutical manufacturing. By owning production facilities for high-potency injectable drugs, which require advanced technology and investment, we are able to undertake contract manufacturing in fields distinctive to our group.」

「Production capacity 12 million syringe formulations per year Scheduled completion June 2026 Scheduled start of operations July 2027」

「Among the main contract-manufacturing products, injectable drugs for which preparations to increase production had been under way performed steadily, owing in part to a further increase in production from January this year and higher sales volumes.」

「The No. 2 Plant will be a high-potency sterile formulation plant designed for mass production of 12 million 1–2 mL prefilled syringes per year.」

「In the pharmaceuticals manufacturing and marketing business, we are focusing on manufacturing high-potency injectable drugs, a distinguishing feature of the business, while working to further improve productivity.」

「Building on the strengths of our pharmaceutical manufacturing and marketing business, our group is focusing on manufacturing highly potent injectables, where substitution by generic drugs has been relatively limited, while working to further improve productivity and ensure a stable supply of pharmaceuticals required by healthcare professionals.」

「In the injectable drug business, a distinguishing feature of our group's pharmaceuticals manufacturing and marketing operations, we are focusing on manufacturing high-potency injectable drugs, for which substitution by generic drugs has progressed relatively slowly, while working to further improve productivity and ensure a stable supply of medicines required by healthcare professionals.」

「In injectable drugs, a distinguishing feature of our group's pharmaceuticals manufacturing and marketing business, we are focusing on manufacturing high-potency injectable drugs, for which substitution by generic drugs has progressed relatively slowly, while working to further improve productivity and ensure a stable supply of medicines required by healthcare professionals.」

「Injectable drugs, a distinguishing feature of our group's pharmaceuticals manufacturing and marketing business, have a low divergence from prevailing market prices. In particular, we are focusing on manufacturing high-potency injectable drugs, for which substitution by generic drugs has progressed relatively slowly, while working to further improve productivity.」

「In the pharmaceuticals manufacturing and marketing business, in addition to our existing injectable manufacturing operations, we intend to focus on supplying injectable formulations in the high-potency segment, centered on the newly established Zao Plant of コーアイセイ株式会社.」

「In the pharmaceuticals manufacturing and marketing business, in addition to our existing injectable manufacturing operations, we intend to focus on supplying injectable formulations in the high-potency segment, centered on the newly established Zao Plant of コーアイセイ株式会社.」

「Sales grew substantially after we began increasing production of Maxacalcitol Intravenous Injection for Dialysis, which was launched in January 2018.」

「Production has also begun at the high-potency injectable drug plant of Maxacalcitol Intravenous Injection for Dialysis. We have established a two-shift production system to increase output and expect this to make a further contribution to results.」

「In addition to our existing injectable manufacturing operations, we intend to focus on supplying injectable formulations in the high-potency segment, centered on the newly established Zao Plant of コーアイセイ株式会社.」